# Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure

Study · id `cardio:ct-nct07263035` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07263035](<https://clinicaltrials.gov/study/NCT07263035>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07263035

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.

## Technical summary

Registry record NCT07263035. Randomized; no masking; primary purpose treatment. Start 2026-04-01 (actual); primary completion 2027-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 600 participants (planned count; ClinicalTrials.gov record NCT07263035, source copy `cardio:ctgov-nct07263035-2026-04-09`, retrieved 2026-10-26)
- Started: 2026-04-01 (actual) (ClinicalTrials.gov record NCT07263035, source copy `cardio:ctgov-nct07263035-2026-04-09`, retrieved 2026-10-26)
- Primary completion: 2027-06-01 (anticipated) (ClinicalTrials.gov record NCT07263035, source copy `cardio:ctgov-nct07263035-2026-04-09`, retrieved 2026-10-26)
- Completion: 2027-09-01 (anticipated) (ClinicalTrials.gov record NCT07263035, source copy `cardio:ctgov-nct07263035-2026-04-09`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07263035, source copy `cardio:ctgov-nct07263035-2026-04-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07263035-2026-04-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure
- Acronym: US-DASH
- Condition: Heart Failure
- Condition: Heart Failure - NYHA II - IV
- Condition: Heart Failure Acute
- Condition: Acute Heart Failure (AHF)
- Intervention (Drug): Furosemide intravenous solution
- Intervention (Drug): Furosemide intravenous solution
- Intervention (Drug): Furosemide intravenous solution
- Lead sponsor: Lakeland Regional Health Systems, Inc.
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

## Provenance

Content hash: 4524c08a7692d376b669ccfc9f84c18c5358c0cb4cf0d22cbda49ec70bb58284
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
